Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results
Short answer: If you can absorb B12, high-dose oral B12 (1,0002,000 mcg/day) is as effective as intramuscular injections for normalizing levels in most people (AAFP
A licensed nurse will give you some paperwork to fill out to get your medical history
The NCAAs banned substance list applies to all student-athletes participating in NCAA-sanctioned sports across all divisions (I, II, and III)
Understanding lyophilized versus liquid peptides helps clarify why powder form is preferred for storage and shipping
Note: Prolonged B12 deficiency can lead to permanent nerve damage
US$ 23.14
US$ 29.73
US$ 23.21
